SCHEMBL18006558

SCHEMBL18006558

Cc1ccc(-c2csc(N)n2)nc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.59
CCR5 P51681 1/20 0.59
CCR8 P51685 1/20 0.59
HDAC6 Q9UBN7 1/20 0.59
NPC1 O15118 5/20 0.50
ALDH1A1 P00352 5/20 0.50
MAPT P10636 4/20 0.50
HSD17B10 Q99714 2/20 0.50
LTA4H P09960 2/20 0.50
GFER P55789 1/20 0.50
SMN1; SMN2 Q16637 5/20 0.45
NOS1 P29475 1/20 0.45
NOS3 P29474 1/20 0.45
NOS2 P35228 1/20 0.45
RAB9A P51151 3/20 0.45
SLC2A1 P11166 1/20 0.44
METAP2 P50579 1/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
LMNA P02545 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18113759 0.78 ALDH1A1 (0.59) NPC1ALDH1A1MAPTHSD17B10LTA4H
SCHEMBL18236297 0.78 MAPT (0.58) NPC1ALDH1A1MAPTHSD17B10LTA4H
SCHEMBL21484651 0.77 NPC1 (0.63) NPC1ALDH1A1MAPTHSD17B10LTA4H
Abametapir SCHEMBL29374261 0.77 CCR1 (1.00) CCR1CCR5CCR8HDAC6MAPT
Abametapir SCHEMBL351152 0.77 CCR1 (1.00) CCR1CCR5CCR8HDAC6MAPT
SCHEMBL13623572 0.75 CCR1 (0.50) CCR1CCR5CCR8HDAC6NPC1
SCHEMBL24358021 0.75 MEN1 (0.52) NPC1ALDH1A1MAPTHSD17B10LTA4H
SCHEMBL29601739 0.75 MEN1 (0.52) NPC1ALDH1A1MAPTHSD17B10LTA4H
SCHEMBL231094 0.75 LTA4H (0.80) NPC1ALDH1A1MAPTHSD17B10LTA4H
SCHEMBL10719025 0.74 ALDH1A1 (0.61) NPC1ALDH1A1MAPTHSD17B10LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3259256-A1 COMPOUNDS AND METHODS FOR INDUCING BROWNING OF WHITE ADIPOSE TISSUE Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (CN) 2017-12-27 EP claimed
WO-2016131192-A1 COMPOUNDS AND METHODS FOR INDUCING BROWNING OF WHITE ADIPOSE TISSUE GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) 2016-08-25 WO claimed
US-11453663-B2 Substituted propanamides as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2022-09-27 US disclosed
US-20220073507-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-03-10 US disclosed
CN-112351983-A Substituted propionamides as inhibitors of nucleases 马萨里克大学 2021-02-09 CN disclosed
EP-3556756-B1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2020-10-07 EP disclosed
EP-3556756-B1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2020-10-07 EP disclosed
WO-2019201867-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
WO-2019201867-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
EP-3556756-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed
EP-3556756-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed
EP-3259256-A1 COMPOUNDS AND METHODS FOR INDUCING BROWNING OF WHITE ADIPOSE TISSUE Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (CN) 2017-12-27 EP disclosed
WO-2016131192-A1 COMPOUNDS AND METHODS FOR INDUCING BROWNING OF WHITE ADIPOSE TISSUE GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) 2016-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073507-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES DNASE1, RNASEH1, FEN1 CCR1 3723/4885CCR5 4757/4885CCR8 4603/4885
US-11453663-B2 Substituted propanamides as inhibitors of nucleases DNASE1, RNASEH1, FEN1 CCR1 3723/4885CCR5 4757/4885CCR8 4603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.